Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06052059 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)
A Phase 3 study of Ulcerative Colitis, sponsored by Merck Sharp & Dohme.
- Active
- Registry status
- Phase 3
- Development phase
- 1,020
- Enrollment target
- 20
- Study locations
NCT06052059 is a Phase 3 study of Ulcerative Colitis that is active but no longer recruiting, run by Merck Sharp & Dohme. The registered enrollment target is 1,020 participants, below the 2,049-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (50% lower). The trial reports 20 study locations across 7 states.
The verdict
NCT06052059, a Phase 3 study of Ulcerative Colitis, is active but no longer recruiting, sponsored by Merck Sharp & Dohme.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 1,020 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this protocol is to evaluate the efficacy of tulisokibart in participants with moderately to severely active ulcerative colitis. Study 1's primary hypotheses are that at least 1 tulisokibart dose level is superior to Placebo in the proportion of participants achieving clinical remission according to the Modified Mayo Score at Week 12, and that at least 1 tulisokibart dose level is superior to Placebo in the proportion of participants achieving clinical remission according to the Modified Mayo Score at week 52. Study 2's primary hypothesis is that at least 1 tulisokibart dose level is superior to Placebo in the proportion of participants achieving clinical remission according to the Modified Mayo Score at Week 12.
Conditions Studied
Interventions
- DRUG IV Placebo
- DRUG IV Tulisokibart
- DRUG SC Tulisokibart
- DRUG SC Placebo
Study Locations (20)
California
- Clinnova Research ( Site 3803) - Anaheim
- Southern California Research Center ( Site 3828) - Coronado
- UCSD - Altman Clinical and Translational Research Institute (ACTRI) ( Site 0113) - La Jolla
- Cedars-Sinai Medical Center ( Site 0119) - Los Angeles
- University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 3851) - Orange
Colorado
- University of Colorado Anschutz Medical Campus-Division of Gastroenterology and Hepatology ( Site 0172) - Aurora
- Peak Gastroenterology Associates ( Site 0116) - Colorado Springs
- South Denver Gastroenterology, PC ( Site 3849) - Englewood
- Rocky Mountain Gastroenterology/Topography Health ( Site 3838) - Littleton
Arizona
- Research Solutions of Arizona ( Site 3816) - Litchfield Park
- One of a Kind Clinical Research Center ( Site 3852) - Scottsdale
- GI Alliance - Sun City ( Site 0103) - Sun City
Connecticut
- Connecticut Clinical Research Institute ( Site 0126) - Bristol
- Medical Research Center of Connecticut ( Site 0151) - Hamden
- Yale University School of Medicine-Digestive Disease ( Site 0163) - New Haven
Alabama
- Digestive Health Specialists ( Site 0135) - Dothan
- IMC-Gulf Coast Gastroenterology ( Site 0157) - Fairhope
Florida
- Gastroenterology Consultants of Clearwater ( Site 0152) - Clearwater
- University of Florida College of Medicine-Gastroenterology ( Site 3821) - Gainesville
District of Columbia
- Emerson Clinical Research Institute ( Site 3820) - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,020 participants |
| Start Date | 2023-10-25 |
| Est. Completion | 2029-08-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06052059
The ClinicalTrials.gov registry entry for NCT06052059 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 1,020 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,049-participant average among 122 other Ulcerative Colitis trials with a reported enrollment target (50% lower). The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Ulcerative Colitis appearing as the primary indexed condition, and to 4 interventions - of which IV Placebo is the first listed.
NCT06052059 reports 20 study locations spanning 7 distinct geographic areas - top geographies include California, Colorado, Arizona.
Frequently Asked Questions
What is clinical trial NCT06052059 about?
NCT06052059 is a clinical study titled "A Study to Evaluate Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderately to Severely Active Ulcerative Colitis (MK-7240-001)". The purpose of this protocol is to evaluate the efficacy of tulisokibart in participants with moderately to severely active ulcerative colitis. Study 1's primary hypotheses are that at least 1 tulisokibart dose level is superior to Placebo in the proportion of participants achieving clinical remissi...
What is the current status of trial NCT06052059?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 1,020 participants. The study started on 2023-10-25. Estimated completion is 2029-08-01.
What conditions does trial NCT06052059 study?
This clinical trial studies the following conditions: Ulcerative Colitis.
What interventions are being tested in trial NCT06052059?
The interventions under investigation include: IV Placebo (DRUG), IV Tulisokibart (DRUG), SC Tulisokibart (DRUG), SC Placebo (DRUG).
Who is sponsoring clinical trial NCT06052059?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06052059 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Connecticut. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Ulcerative Colitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
An Induction Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
RECRUITING · Phase 3
-
A Study to Assess the Change in Disease Activity in Adult Participants With Moderate to Severe Ulcerative Colitis Treated With Risankizumab Compared to Vedolizumab
RECRUITING · Phase 3
-
Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study
RECRUITING · Phase 3
-
A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Ulcerative Colitis
RECRUITING · Phase 3
-
A Study of Vedolizumab in Children and Teenagers With Ulcerative Colitis or Crohn's Disease
RECRUITING · Phase 3
-
A Study to Learn More About How Risankizumab Works in Young Participants With Ulcerative Colitis
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.